 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker 'ZVSA') ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin...

ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")

ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit PR Newswire WESTON...

ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit

SEC Declares Form S-4 Registration Statement 'Effective' for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. SEC Declares Form S-4 Registration Statement 'Effective' for Proposed Business Combination of Larkspur Health...

SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference PR Newswire WESTON, Fla. and BRIDGEWATER, N.J., Oct. 28, 2022 Mr. Glover will be joining four...

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference

ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update PR Newswire BRIDGEWATER, N.J...

ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update

Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC...

Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging

Karpus Management Inc. acquired a new stake in Larkspur Health Acquisition Corp. (NASDAQ:LSPR  Get Rating) during the first quarter, HoldingsChannel.com reports. The fund acquired 44,000 shares of the companys stock, valued at approximately $435,000. Other institutional investors also ...

Karpus Management Inc. Takes $435,000 Position in Larkspur Health Acquisition Corp. (NASDAQ:LSPR)

Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics PR...

Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics

ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper PR Newswire WESTON, Fla. and BRIDGEWATER...

ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, LSPR, CVET, RADA SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, LSPR, CVET, RADA PR Newswire NEW YORK, July 21, 2022 NEW YORK, July 21, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, LSPR, CVET, RADA

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It leverages advanced & proprietary technologies to develop product candidates in the areas of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

Watchers	4
52-Wk Low	$9.25
52-Wk High	$25.00

Market Cap	$2.69M
Volume (M)	122,046.00
52-Wk High	$25.00
52-Wk Low	$9.25

LSPR Larkspur Health Acquisition Corp - Ordinary Shares - Class A

About

Feed

News

Fundamentals